KIT Exon 9 Mutation

CI-VAR-00001027Explore in graph →CIViC 509

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor11
KIT Exon 11 Mutation AND KIT Exon 9 Mutation	Imatinib	Predictive	C	Supports Sensitivity Response	4	submitted	EID12949 This study describes a case report of a patient with a gastrointestinal stromal tumor who was prescribed neoadjuvant imatinib and had a pathogenic complete response. A 41-year-old female patient with … (full text at CIViC) PMID 37305871 · Rekaya et al., 2023 · Open in CIViC	civic
KIT Exon 11 Mutation OR KIT Exon 9 Mutation OR PDGFRA Exon 18 Mutation	Sorafenib	Predictive	B	Supports Sensitivity Response	2	submitted	EID11327 In this phase II study, 31 patients with histologically confirmed, metastatic GIST who failed after previous treatments involving both imatinib and sunitinib were enrolled. Tumour samples from 20 of t… (full text at CIViC) PMID 22270258 · Park et al., 2012 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.